According to the latest public documents from the U.S. Securities and Exchange Commission (SEC), biopharmaceutical company Contineum Therapeutics Inc. has launched a new stock offering plan.

The company plans to publicly offer its Class A common stock through the underwriter Leerink Partners, with a maximum fundraising scale of up to 100 million USD. This financing plan aims to provide funding support for the company's clinical-stage research and development projects, further advancing the development process of its drugs for the treatment of neurological diseases. Specific issuance terms, including the offering price, number of shares, and final fundraising scale, will be determined based on market conditions.